Back to today’s briefing

Story perspectives

GSK Acquires Promising Liver Disease Drug for $2 Billion

5/15/2025

35 4

Summary

Story summary

GSK is set to make waves in the medical field by acquiring efimosfermin, a promising treatment for steatotic liver disease, from Boston Pharmaceuticals for up to $2 billion. This strategic move includes a hefty $1.2 billion upfront payment and additional milestone payments of $800 million, with the drug anticipated to hit the market in 2029, bolstering GSK's hepatology portfolio.

1 of 1

Story summary

GSK is set to make waves in the medical field by acquiring efimosfermin, a promising treatment for steatotic liver disease, from Boston Pharmaceuticals for up to $2 billion. This strategic move includes a hefty $1.2 billion upfront payment and additional milestone payments of $800 million, with the drug anticipated to hit the market in 2029, bolstering GSK's hepatology portfolio.